secwatch.observer — SEC 8-K summary
======================================

Issuer:     Turn Therapeutics Inc. (TTRX)
CIK:        0002023016
Form:       8-K
Filed at:   2025-10-02T23:59:59+00:00
Accession:  0001104659-25-096003
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.03, 5.03, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Turn Therapeutics effects direct listing on Nasdaq; appoints two independent directors
--------------------------------------------------------------------------------

- SEC declared effective S-1 for direct listing of up to 17,868,760 shares of common stock on Nasdaq Global Market.
- Entered Stockholders Agreement with CEO Bradley Burnam and BEB Holdings requiring holder consent for major actions while they hold >=10% shares.
- Granted registration rights to CEO/BEB Holdings including demand and piggyback registration rights.
- Appointed Arthur Golden and Dr. Kent Kester as independent directors; Golden chairs Compensation Committee, Kester on Audit and Compensation.
- Executed employment agreements with CEO Bradley Burnam and Zuraiz Chaudhary.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023016/000110465925096003/0001104659-25-096003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023016/000110465925096003/tm2527800d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-096003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer